Background: Lysosomal storage disorders (LSDs) comprise a heterogeneous group of inherited metabolic diseases that lead to severe, irreversible complications if diagnosis is delayed. Newborn screening (NBS) provides a crucial opportunity for early identification and timely initiation of disease-modifying interventions. Methods: We analyzed 234,642 newborns screened over a 10-year period in Tuscany, Italy, for Fabry disease (FD), Pompe disease (PD), and mucopolysaccharidosis type I (MPS I), using evolving methodologies, including tandem mass spectrometry and digital microfluidics-based assays. We report the epidemiological data, molecular characterization, and the clinical impact of our screening program. Approximately 18% of screened newborns were of non-Italian origin, predominantly from Chinese, North African, and sub-Saharan African communities, providing unique insights into the genetic landscape of LSDs in a multiethnic population. Results: We identified 422 initial positive screens (recall rate 0.18%), of which 170 were confirmed on second dried blood spot (DBS). Molecular analysis revealed 17 late-onset PD individuals (incidence 1:13,802), 24 FD individuals, including five classical and 19 late-onset phenotypes (incidence 1:9776 total, 1:46,928 classical). No MPS I cases were confirmed, despite 45 positive initial screens. Nineteen novel variants were detected across the three genes: 4 in GAA, 5 in GLA, and 10 in IDUA. Evidence of regional founder effects emerged for the GLA variants c.335G > A and c.640-823 T > C. Conclusions: Our 10-year experience demonstrates the effectiveness of NBS for LSDs while highlighting important challenges, particularly the high burden of pseudodeficiencies and variants of uncertain significance (VUS). In MPS I screening, the substantial prevalence of pseudodeficiency alleles underscores the need for robust second-tier testing strategies to improve positive predictive value, especially in ethnically diverse populations.
Over ten years of newborn screening for LSDs in Tuscany (Italy): Epidemiology, novel variants, and the pseudodeficiency burden / Malvagia, Sabrina; Daniotti, Marta; Tonin, Rodolfo; Ferri, Lorenzo; Ombrone, Daniela; Forni, Giulia; Scolamiero, Emanuela; Funghini, Silvia; Rinaldi, Marina; Falliano, Silvia; Paoli, Antonella; Mura, Massimo; Raspini, Francesca; Poggiali, Sara; Scaturro, Giusi; Sacchini, Michele; Donati, Maria Alice; Procopio, Elena; Guerrini, Renzo; Morrone, Amelia; la Marca, Giancarlo. - In: MOLECULAR GENETICS AND METABOLISM. - ISSN 1096-7206. - ELETTRONICO. - 148:(2026), pp. 110114.0-110114.0. [10.1016/j.ymgme.2026.110114]
Over ten years of newborn screening for LSDs in Tuscany (Italy): Epidemiology, novel variants, and the pseudodeficiency burden
Malvagia, Sabrina;Daniotti, Marta;Tonin, Rodolfo;Ombrone, Daniela;Forni, Giulia;Scolamiero, Emanuela;Funghini, Silvia;Rinaldi, Marina;Donati, Maria Alice;Procopio, Elena;Guerrini, Renzo;Morrone, Amelia;la Marca, Giancarlo
2026
Abstract
Background: Lysosomal storage disorders (LSDs) comprise a heterogeneous group of inherited metabolic diseases that lead to severe, irreversible complications if diagnosis is delayed. Newborn screening (NBS) provides a crucial opportunity for early identification and timely initiation of disease-modifying interventions. Methods: We analyzed 234,642 newborns screened over a 10-year period in Tuscany, Italy, for Fabry disease (FD), Pompe disease (PD), and mucopolysaccharidosis type I (MPS I), using evolving methodologies, including tandem mass spectrometry and digital microfluidics-based assays. We report the epidemiological data, molecular characterization, and the clinical impact of our screening program. Approximately 18% of screened newborns were of non-Italian origin, predominantly from Chinese, North African, and sub-Saharan African communities, providing unique insights into the genetic landscape of LSDs in a multiethnic population. Results: We identified 422 initial positive screens (recall rate 0.18%), of which 170 were confirmed on second dried blood spot (DBS). Molecular analysis revealed 17 late-onset PD individuals (incidence 1:13,802), 24 FD individuals, including five classical and 19 late-onset phenotypes (incidence 1:9776 total, 1:46,928 classical). No MPS I cases were confirmed, despite 45 positive initial screens. Nineteen novel variants were detected across the three genes: 4 in GAA, 5 in GLA, and 10 in IDUA. Evidence of regional founder effects emerged for the GLA variants c.335G > A and c.640-823 T > C. Conclusions: Our 10-year experience demonstrates the effectiveness of NBS for LSDs while highlighting important challenges, particularly the high burden of pseudodeficiencies and variants of uncertain significance (VUS). In MPS I screening, the substantial prevalence of pseudodeficiency alleles underscores the need for robust second-tier testing strategies to improve positive predictive value, especially in ethnically diverse populations.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



